ClinicalTrials.gg
Not yet recruitingNCT07343518Updated Jan 15, 2026

Effects of Sulforaphane Supplementation on Athletic Performance

An interventional study of Fatigue protocol in Nutrition and Sports, sponsored by University of Maia. Not yet recruiting. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by University of Maia · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

Considering the promising effects observed and the scarce and incipient scientific background of SFN in sports, the present study aims to evaluate the effects of SFN supplementation on fatigue, EIMD and recovery in trained individuals. In particular, outcomes such as time to exhaustion (TTE), and perceptual questionnaires of muscle soreness, recovery, and fatigue will be assessed, aiming to explore the effectiveness of SFN.

02

Conditions studied

  • Nutrition
  • Sports

Browse trials for

Keywords

  • sulforaphane
  • fatigue
  • athletic performance
03

In context

Fatigue

2,234 studies on the registry are indexed under Fatigue; 430 are open to participants now.

This study's planned enrollment of 20 is below the median of 54 across 1,762 interventional studies indexed under Fatigue.

Browse Fatigue studies →

Lead sponsor

University of Maia is the lead sponsor of 21 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physically active individuals (engaging in exercise 3 or more times per week)

Exclusion criteria

Exclusion Criteria:

  • Individuals that experience musculoskeletal injuries or have experienced in the past 3 months
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Sulforaphane

    Sulforaphane supplementation (Nomio)

    Other: Fatigue protocol

  • Placebo comparator
    Placebo

    Placebo intervention

    Other: Fatigue protocol

Interventions

  • OtherFatigue protocol

    Fatigue protocol comprising 6 sets of 30 seconds at 120% of velocity of maximal oxygen consumption

06

What researchers measure

Primary outcomes

  1. time to exhaustion

    Time frame: 24 hours

Secondary outcomes

  1. Rating of Fatigue Scale

    Time frame: Baseline, 30 minutes, 24 hours

  2. Total Quality Recovery Scale

    Time frame: Baseline, 30 minutes, 24 hours

  3. Muscle soreness (Visual analogue scale)

    Time frame: Baseline, 30 minutes, 24 hours

  4. Rating of perceived exertion scale

    Time frame: 30 minutes

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Apr 2026, 2 months later.

Of 937 non-industry interventional studies with no phase under Fatigue, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 2 months is below that.

Counting every sponsor, half of 990 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2025
First posted
Jan 15, 2026
StartEst.
Jan 2, 2026
Primary completionEst.
Apr 1, 2026
CompletionEst.
May 1, 2026
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07343518
Lead sponsor
University of Maia
Responsible party
Filipe Silvano Pinto Maia (Principal Investigator, University of Maia) — Principal investigator
First posted
Jan 15, 2026
Start date
Jan 2, 2026 (estimated)
Primary completion
Apr 1, 2026 (estimated)
Completion
May 1, 2026 (estimated)
Last update
Jan 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion